Filing Analysis
VASO Corporation has completed the sale of its wholly owned subsidiary, NetWolves Network Services LLC, to COEO Solutions, LLC. This 8-K/A filing provides the required unaudited pro forma financial information resulting from this divestiture.
🚩 Red Flags
- Divestiture of a wholly owned subsidiary can sometimes indicate a shift in corporate strategy or a need for immediate liquidity to fund operations/debt.
📋 Key Facts
- Completed sale of all issued and outstanding membership interests of NetWolves Network Services LLC on July 31, 2026.
- The buyer is COEO Solutions, LLC.
- This filing is an Amendment (8-K/A) to provide unaudited pro forma condensed consolidated financial information per Item 9.01(b).
- NetWolves was a wholly owned subsidiary of VasoTechnology, Inc., which in turn is a wholly owned subsidiary of VASO Corp.
VASO Corporation has entered into an agreement to sell its wholly owned subsidiary, NetWolves Network Services LLC, to COEO Solutions, LLC. The transaction involves the sale of all issued and outstanding membership interests for a base price of $14.5 million in cash.
🚩 Red Flags
- Asset disposition reduces the company's overall scale and operational footprint.
- The sale of a wholly owned subsidiary may indicate a shift in corporate strategy or a need for immediate liquidity.
📋 Key Facts
- Transaction Date: July 31, 2026
- Buyer: COEO Solutions, LLC
- Asset Sold: All issued and outstanding membership interests of NetWolves Network Services LLC
- Base Purchase Price: $14,500,000.00 in cash
- Adjustments: Subject to customary post-closing adjustments (net working capital, closing cash, indebtedness, etc.)
- NetWolves Business: Managed network provider and multi-technology solutions design/delivery.
VASO Corporation announced the appointment of Shaun McMeans to its Board of Directors as a Class III director, effective July 23, 2026. Mr. McMeans is a financial expert who will serve on the audit committee.
📋 Key Facts
- Shaun McMeans appointed as Class III director effective July 23, 2026.
- McMeans will serve as a member of the Board's audit committee and is designated as a 'financial expert'.
- Compensation includes a pro-rated portion of non-employee director compensation and a one-time grant of 100,000 shares of VASO common stock.
- McMeans currently serves as CFO of Nabsys and was previously CFO of HTG Molecular Diagnostics, Inc.
VASO Corporation held its Annual Meeting of Shareholders on December 17, 2025. The meeting resulted in the election of three Class II directors and the approval of non-binding advisory proposals regarding executive compensation frequency.
📋 Key Facts
- Annual Meeting held on December 17, 2025.
- Three Class II directors elected: Behnam Movaseghi, Jane Moen, and Leon Dembo for three-year terms.
- Shareholders approved the 'Say on Pay' advisory proposal regarding executive compensation.
- Shareholders voted to recommend that 'Say on Pay' votes occur every three years (56% in favor).
- Total shares entitled to vote: 175,953,035; Total shares voted: 120,208,576.
VASO Corporation announced on November 19, 2025, that it has entered into an agreement to sell its wholly-owned subsidiary, VasoHealthcare IT Corp.
🚩 Red Flags
- Divestiture of a wholly-owned subsidiary can sometimes indicate a need for immediate liquidity or a shift away from core business operations, though the strategic rationale is not provided in this summary filing.
📋 Key Facts
- Transaction date: November 19, 2025
- Asset being sold: Wholly-owned subsidiary, VasoHealthcare IT Corp.
- Filing includes a press release as Exhibit 99.1 regarding the transaction.
VASO Corp announced a significant restructuring of its executive leadership effective January 1, 2025. This includes the appointment of Jane Moen as COO and the transition of Michael Beecher from Co-CFO to a financial advisor role.
🚩 Red Flags
- Departure of the Co-CFO from his primary executive role may indicate internal restructuring or shifts in financial oversight.
- The transition of a CFO to 'financial advisor' rather than leaving the company entirely can sometimes signal a negotiated exit or a period of instability.
📋 Key Facts
- Jane Moen appointed Chief Operating Officer (COO) effective Jan 1, 2025; she will also remain President of Vaso Diagnostics, Inc. d/b/a VasoHealthcare.
- Peter C. Castle transitioned from COO to President of the subsidiary VasoTechnology, Inc.
- Michael Beecher ceased serving as Co-Chief Financial Officer and Secretary on Jan 1, 2025; he remains an employee as a financial advisor.
- Jonathan Newton appointed as sole Chief Financial Officer (CFO), Treasurer, and Secretary.
VASO Corporation has officially terminated its Business Combination Agreement with Achari Ventures Holdings Corp. I, which was originally entered into on December 6, 2023. This termination represents a failure of the previously announced merger/SPAC-style transaction.
🚩 Red Flags
- Termination of a major business combination agreement (failed merger/SPAC deal).
- Significant strategic setback for the company's growth trajectory.
- Potential loss of capital or resources previously allocated toward the transaction.
📋 Key Facts
- Termination notice for the Business Combination Agreement was provided to Achari on September 17, 2024.
- The original agreement (dated Dec 6, 2023) intended for Vaso to become a wholly owned subsidiary of Achari via Merger Sub.
- A press release regarding the termination was issued on September 18, 2024.
VASO Corp successfully held a special meeting on September 10, 2024, where stockholders approved the definitive business combination agreement with Achari Ventures Holdings Corp I. The company expects to consummate the transaction promptly and begin trading on Nasdaq under the ticker 'VASO'.
🚩 Red Flags
- The filing involves a business combination/merger structure which typically carries high execution risk and potential dilution for existing shareholders.
📋 Key Facts
- Stockholders approved the Business Combination Proposal (Proposal No. 1) with 125,596,668 votes in favor.
- The Special Meeting reached a quorum with 73.6% of voting power represented.
- Director elections for Jun Ma and David Lieberman were both approved by significant majorities.
- A Ratification Proposal (Proposal No. 3) was also approved by stockholders.
- Post-combination, common stock is expected to trade on Nasdaq as 'VASO' and warrants as 'VASOW'.
VASO Corporation announced the adjournment of its Special Meeting of stockholders, originally scheduled for August 26, 2024. The meeting is rescheduled to September 10, 2024, to vote on a proposed business combination with Achari Ventures Holdings Corp. I.
🚩 Red Flags
- Adjournment of a special meeting can sometimes indicate delays in securing sufficient proxy votes or pending regulatory/financing hurdles.
📋 Key Facts
- The Special Meeting was adjourned from August 26, 2024, to September 10, 2024, at 10:00 a.m. ET.
- The meeting location is Lever House, 390 Park Avenue, Third Floor, New York, NY.
- The purpose of the meeting includes voting on a Business Combination Agreement dated December 6, 2023, with Achari Ventures Holdings Corp. I and its merger sub.
- The record date for the Special Meeting remains July 15, 2024.
- The company has filed a Definitive Proxy Statement regarding these proposals.
Vaso Corporation has filed unaudited pro forma condensed financial information regarding a proposed business combination with Achari Ventures Holdings Corp. I and Achari Merger Sub, Inc. The filing provides a look-back at how the combined entities would have performed as of June 30, 2024, and December 31, 2023.
🚩 Red Flags
- The pro forma information is for informational purposes only and does not guarantee future results or actual historical performance of a combined entity.
📋 Key Facts
- Proposed business combination involving Vaso Corporation, Achari Ventures Holdings Corp. I, and Achari Merger Sub, Inc.
- Filing includes unaudited pro forma condensed combined financial information for the six months ended June 30, 2024, and the year ended December 31, 2023.
- Pro forma data assumes completion of the Business Combination as if it had occurred on January 1, 2023.
- The filing is intended to satisfy requirements under Rule 425 (written communication) and Rule 14a-12 (soliciting material).